Amgen appeals over orphan drug biosimilar ban

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Amgen appeals over orphan drug biosimilar ban

Vials of liquid on a white table and the logo of a large pharmaceutical company.

Alexion obtained a preliminary injunction in Munich barring Amgen from selling a biosimilar version of its antibody drug

Amgen has appealed against a German court order issued last Friday, August 4, after having earlier been forced to pull a drug for a rare blood disorder from the German market.

Alexion, a UK-based biologics developer owned by AstraZeneca, asserted orphan drug exclusivity (ODE) rights on its antibody treatment Soliris (eculizumab) against Amgen at the Munich Regional Court earlier this year.

Soliris is approved by the European Medicines Agency (EMA) to treat paroxysmal nocturnal haemoglobinuria (PNH), a chronic blood condition, as well as other rare diseases.

The EMA approved Bekemv, Amgen’s biosimilar version of Soliris, for the treatment of PNH in April this year, after Alexion’s monopoly on that use of the drug expired.

But in May, days after Bekemv launched in Germany, Alexion obtained a preliminary injunction at the Munich court that restricted Amgen’s sale of the drug.

Alexion claimed there was a risk that Bekemv would be used for the off-label treatment of conditions other than PNH, for which Alexion still has exclusive rights.

Soliris is protected by ODE until later this year for atypical haemolytic uraemic syndrome, until 2027 for generalised myasthenia gravis, and until 2029 for neuromyelitis optica spectrum disorder.

The Munich court upheld May’s preliminary order last Friday, August 4, after finding that Amgen had contributed to the risk of off-label use of Bekemv by sending letters of recommendation to medical practitioners.

A spokesperson for Alexion said: "We are pleased with the court’s decision in that it helps protect some of the incentives that propel innovation in the rare disease space.”

Counsel for Amgen said the case was the first time the holder of ODE rights had asserted them against a competitor in Europe.

The court ruled Amgen couldn’t market Bekemv unless it met certain conditions, which its lawyers have described as “unreasonable” and “unbearable”.

Amgen, represented by Osborne Clarke and Bardehle Pagenberg, has appealed against the decision to the Federal Court of Justice.

According to Tilman Müller-Stoy, partner at Bardehle Pagenberg, the injunction is based entirely on the mere danger of off-label use.

The court’s order would require Amgen customers, including hospitals, to contractually agree not to make any off-label use of the drug, Müller-Stoy said.

Alexion has also sued Samsung’s biosimilars unit, Samsung Bioepis, at the same court. A hearing over a preliminary injunction in that case is scheduled for August 16.

The EMA approved Samsung Bioepis’s biosimilar version of eculizumab in May.

more from across site and SHARED ros bottom lb

More from across our site

Exclusive data reveals law firms are failing to go above and beyond for their corporate clients, with in-house counsel saying advisers should consider more transparent billing processes
Arty Rajendra and Gary Moss discuss why ‘thorough and intense’ preparation, plus the odd glass of wine, led to a record FRAND victory for their client
Monday’s coverage includes news of a potentially 'game-changing' trademark development in China and how practitioners are using AI
Managing IP gives a taster of the numbers behind this year’s IP STARS trademark rankings, and looks back at our 2025 award winners
Updates from IP offices, the shifting requirements of in-house counsel, and news of London 2026 were among major talking points on Sunday
Etienne Sanz de Acedo discusses the association’s three-year plan, what he is looking forward to in San Diego, and why London came calling for 2026
Professionals from three organisations reveal what led them to sponsor Brand Action and why doing so can build camaraderie
The results of a UK government consultation on the exhaustion of IP rights and an annual review published by the EPO’s Boards of Appeal were also among the top talking points this week
The decision disregards Perlmutter’s work at the US Copyright Office and comes at a time when strong leadership and expertise are crucial
Sources say the decision to fire Shira Perlmutter raises constitutional concerns and speculate on what the decision could mean for the country’s approach to AI
Gift this article